Introduction {#s001}
============

C[arbapenems are the first-line]{.smallcaps} therapy for infections caused by multidrug-resistant Gram-negative Enterobacteriaceae, especially extended-spectrum β-lactamase-producers.^[@B1]^ In the recent years, however, the emergence of carbapenem-resistant Enterobacteriaceae (CRE) strains has been increasingly reported.^[@B2]^ CRE strains provide a particular challenge because they are resistant to β-lactam agents and there are very limited treatment options for CRE induced diseases. Moreover, these bacterial strains show the potential to spread within healthcare facilities. Infections caused by CRE are associated with high morbidity and mortality rates. In a meta-analysis of deaths attributable to CRE infections, CRE-attributable deaths varied from 26% to 44%.^[@B3],[@B4]^

*Klebsiella pneumoniae* is one of the most common Enterobacteriaceae that causes nosocomial infections, such as septicemia, pneumonia, and urinary tract infection, surgical site infection, and catheter-related infection.^[@B5]^ Among CRE species, carbapenem-resistant *K. pneumoniae* (CRKP) poses a major threat, causing an alarming increase in infection rate over the last years. It has been reported that from 2005 to 2011, the proportion of *K. pneumoniae* isolates resistant to carbapenems increased from 28% to 68.2% in Greece.^[@B6],[@B7]^

Patients infected with CRKP are often chronically and acutely ill, which is associated with high mortality. The mortality of patients with CRKP infection (main blood infection) was up to 70%,^[@B8]^ another study reported that 14-day mortality of 19 patients with bacteremia due to *Klebsiella pneumoniae* carbapenemases (KPC)-producing *K. pneumoniae* was 47%.^[@B9]^ Moreover, the readmission rate of survivors was approximately 72% within 90 days of discharge.^[@B10]^ Infections with such strains are difficult to control, because carbapenemase-resistant genes can potentially spread within and between hospitals via transferable plasmids.^[@B11]^ Therefore, knowledge of risk factors associated with CRKP infection development is important to identify high-risk patients in the prevention of CRKP acquisition. In addition, such knowledge also is essential in the empirical therapeutic decision-making process and in the design of effective control measures to prevent infection.

Several studies have evaluated the risk factors of CRKP infection, but their results remain controversial.^[@B12]^ For example, one study reported that treatment with quinolones is a risk factor of CRKP infection,^[@B16]^ whereas other studies showed no association between the use of quinolones and CRKP infection.^[@B13],[@B14]^ Thus, a meta-analysis is needed to resolve these inconsistent results, because a well-designed and appropriately performed meta-analysis can become a powerful analytical method where both independent and different studies are integrated and their results are pooled, thereby increasing the power of statistical testing and producing information that cannot be drawn from one individual study.^[@B17]^ Accordingly, we performed a meta-analysis to identify the relationship between risk factors and CRKP infection.

Materials and Methods {#s002}
=====================

A meta-analysis of observational studies on risk factors of CRKP infection was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.^[@B18]^ The methodology included data source collection, inclusion and exclusion criteria, data extraction, quality assessment, and statistical analysis.

Data source collection and screening strategy {#s003}
---------------------------------------------

A systematic search of English written articles up to September 2016 that focused on the risk factors of CRKP infection was performed on PubMed/Medline, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and EBSCO. The following search terms were used: (carbapenem-resistant or carbapenemase-producing or KPC) and (*Klebsiella pneumoniae* \[MeSH\] or *Klebsiella pneumoniae*) and (infection \[MeSH\] or infections or infection) and (risk factors \[MeSH\] or factor, risk or factors, risk or risk factor or dangerous factors or hazards or causes).The references to all identified published works were entered into a reference management software program (EndNote, version X7; Thomson Reuters, Toronto, ON, Canada).

Inclusion and exclusion criteria {#s004}
--------------------------------

Two reviewers (P.L. and X.L.) conducted an initial screening of titles and abstracts independently. A second screening was completed through a full-text review by the same reviewers. Subsequently, we compared the screened studies to determine whether they were in accordance with the cross-check method. Any disagreements were addressed by a third party (J.Q.) when necessary.

The inclusion criteria were as follows: (1) studies were about the risk factors for CRKP infection. (2) CRKP was defined as the resistance of *K. pneumoniae* to imipenem, meropenem, or ertapenem based on the susceptibility breakpoints that had been applied by the investigators of each study, which were identified through definite microbiological methods (Vitek automated system, BD Phoenix automated microbiology system, modified Hodge test, disc diffusion method, and E-test), and the definition of infection was explicit. (3) It was a case--control or cohort study in design. (4) The studies were published in English.

Studies were excluded if they were (1) duplicated studies, (2) reviews, reports, or meeting abstracts, (3) studies that did not distinguish the outcomes of infected patients from those of colonized patients, (4) studies that did not provide sufficient information to allow the calculation of odds ratios (ORs) and 95% confidence intervals (CIs).

Data extraction {#s005}
---------------

Three reviewers (P.L., X.L., and K.S.) independently extracted the relevant data according to a previously created data extraction form. The extracted data included (1) the title of studies and years of publication, (2) the first author\'s name and country where the study was implemented, (3) study designs, (4) number of cases and control patients, and (5) all identified risk factors of CRKP infection and ORs of risk factors calculated from both univariate and multivariate logistic regression analyses. The extraction results were evaluated by other reviewers (Y.L. and M.L.), and any disagreements were resolved through discussion.

Quality assessment {#s006}
------------------

The quality of each study was assessed based on the nine-star Newcastle--Ottawa Scale (NOS),^[@B19]^ which included three aspects of methodology assessment: selection of cases (4 items, 4 points), comparability of cases and controls (1 item, 2 points), and ascertainment of exposure to risk factors (3 items, 3 points). Scores of 0--4 points indicated a low-quality research, whereas scores of 5--9 points suggested a high-quality research.^[@B20]^ Three reviewers (S.C., Y.Q., and X.X.) independently assessed the quality of each study, and different opinions on scoring were resolved through discussion among the research group until a consensus was reached.

Statistical analysis {#s007}
--------------------

The meta-analysis was performed using Review Manager (RevMan) software version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) and Stata version 11.0 (StataCorp, College Station, TX). The *χ*^2^ and *I*^2^ statistic tests were used to evaluate the heterogeneity among the included studies. The random-effects model was utilized to combine the results when heterogeneity was present among the studies (*I*^2^ *\>* 50% or *p* \< 0.05). Otherwise, the fixed-effects model would be used. Pooled ORs with a 95% CI were calculated using either a fixed-effects or a random-effects model to compare the risk factors of CRKP infection. The *Z*-test was used to determine the significance of the pooled ORs. The results were considered statistically significant when *p* \< 0.05. Sensitivity analyses were conducted through sequential omission of individual studies and then comparison of the *p* value of pooled ORs. The results were identified as credible when the corresponding *p* value of pooled ORs was not substantially different. Potential publication bias was examined using Egger\'s test through the software Stata version 11.0. Results were considered statistically significant when *p* \< 0.05. In addition, the overall population exposure rate (*P~e~*) was replaced by the pool exposure rate of controls to calculate the population attributable risk proportion (PARP) following the formula: PARP = *P~e~* (OR −1)/\[*P~e~* (OR −1) + 1\].

Results {#s008}
=======

Study selection and characteristics {#s009}
-----------------------------------

Following the literature search and selection, 197 potentially relevant publications up to September 2016 were systematically retrieved from the electronic databases. After the title and abstract reviews, 48 studies were retained, and duplicates, letters, meeting abstracts, case reports, and studies not pertinent to the risk factors of CRKP infection were excluded. Among them, 32 studies that did not match the inclusion criteria were excluded via full-text screening. Finally, 16 studies^[@B13],[@B14],[@B16],[@B21]^ were included in the meta-analysis ([Fig. 1](#f1){ref-type="fig"}). [Table 1](#T1){ref-type="table"} lists the detailed characteristics of the 16 included articles.

![Preferred reporting items for systematic reviews and meta-analysis flowchart of the study identification and selection. CRKP, carbapenem-resistant *Klebsiella pneumoniae.*](fig-1){#f1}

###### 

[Characteristics of Studies Included in the Meta-Analysis]{.smallcaps}

  *Study*            *Study design*   *Period*                      *Study location*   *Case/control, n*   *Mean age (SD or range), case/control, years*               *Male sex, case/control,* n   *Quality assessment*^[a](#tf1){ref-type="table-fn"}^   *Adjusted variables*
  ------------------ ---------------- ----------------------------- ------------------ ------------------- ----------------------------------------------------------- ----------------------------- ------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Falagas, 2007      Case-control     October 2000--May 2006        Greece             53/53               61.5 (18.8)/61.9 (17.2)                                     38/39                         6 points                                               Fluoroquinolones, antipseudomonal penicillins
  Patel, 2008        Case-control     July 2004--June 2006          USA                99/99               60.67 (14.95)/59.39 (13.34)                                 58/58                         7 points                                               Liver disease, renal insufficiency, transplant recipient, receipt of MV, use of CVC, ICU stay, length of stay before infection, cephalosporin, fluoroquinolone, carbapenem, β-lactam and/or β-lactamase inhibitor, monobactam, aminoglycoside
  Wu, 2011           Case-control     July 2006--July 2008          China              39/78               64 (16.0)/56.9 (17.6)                                       28/60                         7 points                                               ICU admission (within 2 weeks), carbapenems, lycopeptides
  Borer, 2012        Case-control     May 2007--January 2010        Israel             42/84               72 (19--91)/72.5 (21--95)^[b](#tf2){ref-type="table-fn"}^   NA                            6 points                                               Previous invasive procedures, diabetes mellitus, solid tumor, tracheostomy, urinary catheter insertion, antipseudomonal penicillin use
  Correa, 2013       Case-control     January 2006--August 2008     Brazil             20/40               59.6/64.9                                                   13/21                         7 points                                               Mean APACHE II score at admission, CVC, mean urinary catheter use, prior antimicrobial use
  Gómez, 2014        Case-control     January 2008--January 2011    Colombia           61/122              42.2 (28.4)/47.3 (24.3)                                     30/75                         8 points                                               Exposure to quinolones, time at risk, charlson index, colonization, enteral nutrition, carbapenems, piperacillin-tazobactam
  Simkins, 2014      Case-control     January 2006--December 2010   USA                13/39               53 (18)/55 (16)                                             7/14                          5 points                                               NA
  Hu, 2016           Case-control     January 2011--June 2013       China              65/65               64.12 (13.69)/59.06 (14.61)                                 45/50                         6 points                                               Age, prior hospitalization, number of antibiotic groups, carbapenems
  Giannella, 2014    Case-control     January 2012--December 2013   Italy              143/752             65 (52--75)/70 (58--81)^[b](#tf2){ref-type="table-fn"}^     84/307                        6 points                                               Admission to ICU, invasive abdominal procedures, chemotherapy/radiation therapy, colonization at site besides stool
  Mouloudi, 2014     Cohort           January 2008--December 2011   Greece             17/34               54 (44--66)/55 (26--44)^[b](#tf2){ref-type="table-fn"}^     10/19                         5 points                                               NA
  Brizendine, 2015   Cohort           2006--2012                    USA                22/64               56 (10.3)/51 (12.8)                                         16/14                         7 points                                               NA
  Candevir, 2015     Cohort           January 2012--December 2012   Turkey             47/51               38 (0--83)/8 (0--86)^[b](#tf2){ref-type="table-fn"}^        31/30                         7 points                                               Third-generation cephalosporin, nasogastric catheter use, Being admitted to neurosurgical ICU
  Freire, 2015       Cohort           January 2009--December 2013   Brazil             25/1,076            59 (21--73)/47 (6--79)^[b](#tf2){ref-type="table-fn"}^      14/571                        6 points                                               Age, double transplant, ureteral stent
  Giannella, 2015    Cohort           June 2010--December 2013      Italy              20/217              63 (2.8)/55 (14)                                            15/143                        7 points                                               Renal replacement therapy, MV \>48 hr, histological recurrence of HCV, CRKP rectal carriage at any time
  Ny, 2015           Cohort           January 2011--December 2013   USA                48/48               70 (36--95)/78 (29--95)^[b](#tf2){ref-type="table-fn"}^     23/25                         7 points                                               NA
  Vardakas, 2015     Cohort           January 2006--October 2009    Greece             73/18               66.3 (14.4)/60.9 (15.6)                                     36/7                          7 points                                               NA

Low-quality research, 0--4 points; high-quality research, 5--9 points.

Age, median (range), years.

APACHE, Acute Physiology and Chronic Health Evaluation; CRKP, carbapenem-resistant *Klebsiella pneumoniae*; CVC, central venous catheter; HCV, hepatitis C virus; ICU, intensive care unit; MV, mechanical ventilation; NA, not available; SD, standard deviation.

A total of 3,627 participants (787 cases and 2,840 controls) were contained in this meta-analysis, and all participants were inpatients. The sample sizes in studies ranged from 51 to 1,101. These included studies were published from 2007 to 2016 in different countries including the United States,^[@B21],[@B23],[@B27],[@B31]^ China,^[@B14],[@B24]^ Brazil,^[@B29],[@B33]^ Italy,^[@B25],[@B30]^ Israel,^[@B22]^ Colombia,^[@B13]^ Turkey,^[@B28]^ and Greece.^[@B16],[@B26],[@B32]^ Of the 16 studies, 6 studies were retrospective cohort study designs,^[@B26],[@B31],[@B32]^ 1 study was a prospective cohort study design,^[@B30]^ and the other 9 studies were case--control designs.^[@B13],[@B14],[@B16],[@B21],[@B33]^ Among those studies, the results of four cohort studies^[@B26],[@B27],[@B31],[@B32]^ and one case--control study^[@B23]^ did not adjust for any potential confounders, whereas the remaining studies adjusted for several conventional risk factors. All studies were considered as high-quality research after assessment via the NOS.

Risk factors of CRKP infection {#s010}
------------------------------

[Table 2](#T2){ref-type="table"} shows the risk factors of CRKP infection and heterogeneity in the meta-analysis. Among the risk factors, length of hospital stay (LOS), days of intensive care unit (ICU) stay, Acute Physiology and Chronic Health Evaluation (APACHE) II score on ICU, and charlson comorbidity index were continuous variables, the rest were binary variables. The size of statistical heterogeneity among the studies was evaluated using *I*^2^ statistics.^[@B34]^ A significant relationship was found between CRKP infections and the following risk factors: longer LOS (OR = 12.92; 95% CI = \[6.84--19.00\]), admission to ICU (OR = 2.48; 95% CI = \[1.90--3.23\]), prior hospitalization (OR = 1.85; 95% CI = \[1.12--3.07\]), longer days of ICU stay (OR = 4.58; 95% CI = \[3.67--5.49\]), transplant recipient (OR = 2.01; 95% CI = \[1.03--3.92\]), steroids use (OR = 1.43; 95% CI = \[1.04--1.96\]), central venous catheter (CVC) use (OR = 2.30; 95% CI = \[1.26--4.19\]), mechanical ventilation (MV) (OR = 2.54 95% CI = \[1.67--3.85\]), presence of tracheostomy (OR = 3.63; 95% CI = \[1.47--9.00\]), and parenteral nutrition use (OR = 2.38; 95% CI = \[1.68--3.36\]); previous antibiotic use (OR = 3.31; 95% CI = \[1.68--6.49\]); carbapenems (OR = 4.01; 95% CI = \[2.59--6.21\]), aminoglycosides (OR = 2.05; 95% CI = \[1.43--2.94\]), glycopeptides (OR = 2.40; 95% CI = \[1.09--5.27\]), quinolones (OR = 2.28; 95% CI = \[1.40--3.70\]), and anti-pseudomonal penicillins (OR = 2.67; 95% CI = \[1.78--4.01\]). [Figure 2](#f2){ref-type="fig"} illustrates a forest plot describing the relationship between carbapenems exposure and CRKP infection.

![Forest plot for the association between exposure to carbapenems and CRKP infection. The individual block squares denote the mean difference for each study of the risk factor exposure to carbapenems, with an area proportional to the amount of statistical information in each study. The *horizontal line* denotes 95% CI. The pooled estimate and its 95% CI are represented by a *diamond*. CI, confidence interval; M-H, Mantel-Haenszel.](fig-2){#f2}

###### 

[Meta-Analysis of Risk Factors of Carbapenem-Resistant *Klebsiella pneumoniae* Infection]{.smallcaps}

                                                                                                                                                                    *Heterogeneity of study design*                         
  ---------------------------------------- ---- ----------- ------------------------------------------------------- ------ ---------------------------------------- --------------------------------- ------- ---- -------- -------
  Prior hospitalization                    3    131/157     1.85 \[1.12--3.07\]                                     2.38   0.02^[\*](#tf5){ref-type="table-fn"}^    0.00                              1.00    0    Fixed    0.374
  LOS                                      10   592/1,402   12.92 \[6.84--19.00\]^[a](#tf4){ref-type="table-fn"}^   4.16   0.000^[\*](#tf5){ref-type="table-fn"}^   36.90                             0.000   76   Random   0.356
  Admission to ICU                         8    466/1,215   2.48 \[1.90--3.23\]                                     6.69   0.000^[\*](#tf5){ref-type="table-fn"}^   14.04                             0.05    50   Fixed    0.219
  Days of ICU stay                         4    193/455     4.58 \[3.67--5.49\]^[a](#tf4){ref-type="table-fn"}^     9.87   0.000^[\*](#tf5){ref-type="table-fn"}^   3.62                              0.31    17   Fixed    0.214
  APACHE II score on ICU admission         4    208/170     0.25 \[−0.98--1.47\]^[a](#tf4){ref-type="table-fn"}^    0.40   0.69                                     2.61                              0.460   0    Fixed    0.870
  Comorbidity                                                                                                                                                                                                               
  DM                                       10   473/1,597   1.31 \[0.97--1.78\]                                     1.78   0.08                                     9.21                              0.42    2    Fixed    0.441
  Malignancy                               5    347/819     0.72 \[0.47--1.11\]                                     1.48   0.14                                     1.48                              0.83    0    Fixed    0.208
  Heart disorders                          4    234/251     1.28 \[0.85--1.92\]                                     1.20   0.23                                     3.71                              0.29    19   Fixed    0.894
  Transplant recipient                     5    348/1,909   2.01 \[1.03--3.92\]                                     2.04   0.04^[\*](#tf5){ref-type="table-fn"}^    11.27                             0.02    65   Random   0.993
  Renal failure                            3    165/169     1.68 \[0.83--3.41\]                                     1.43   0.15                                     1.72                              0.42    0    Fixed    0.314
  Steroid use                              5    328/877     1.43 \[1.04--1.96\]                                     2.23   0.03^[\*](#tf5){ref-type="table-fn"}^    2.13                              0.71    0    Fixed    0.486
  Respiratory disease                      3    129/130     1.38 \[0.72--2.66\]                                     0.98   0.33                                     0.63                              0.73    0    Fixed    0.844
  Liver disease                            3    225/170     1.45 \[0.86--2.44\]                                     1.39   0.17                                     0.95                              0.62    0    Fixed    0.890
  Neurological disorders                   3    190/136     1.43 \[0.87--2.35\]                                     1.40   0.16                                     0.33                              0.85    0    Fixed    0.554
  Charlson comorbidity index               3    252/742     −0.89 \[−2.31--0.53\]^[a](#tf4){ref-type="table-fn"}^   1.23   0.22                                     41.18                             0.000   95   Random   0.290
  Invasive procedures                                                                                                                                                                                                       
   CVC use                                 8    538/1,039   2.30 \[1.26--4.19\]                                     2.71   0.007^[\*](#tf5){ref-type="table-fn"}^   28.23                             0.000   79   Random   0.344
   MV                                      9    577/1,117   2.54 \[1.67--3.85\]                                     4.37   0.000^[\*](#tf5){ref-type="table-fn"}^   20.15                             0.010   60   Random   0.739
   Prior surgery                           7    456/953     1.45 \[0.89--2.36\]                                     1.47   0.14                                     17.37                             0.008   65   Random   0.195
   Urinary catheter                        7    388/986     1.60 \[0.86--2.98\]                                     1.50   1.13                                     28.71                             0.000   79   Random   0.305
   Tracheostomy                            5    243/385     3.63 \[1.47--9.00\]                                     2.79   0.005^[\*](#tf5){ref-type="table-fn"}^   13.73                             0.008   71   Random   0.036
   Parenteral nutrition                    3    275/712     2.38 \[1.68--3.36\]                                     4.90   0.000^[\*](#tf5){ref-type="table-fn"}^   2.27                              0.320   12   Fixed    0.852
   Previous antibiotic use                 10   569/1,295   3.31 \[1.68--6.49\]                                     3.47   0.000^[\*](#tf5){ref-type="table-fn"}^   32.25                             0.000   72   Random   0.094
  Antibiotic                                                                                                                                                                                                                
   Carbapenems                             12   690/1,437   4.01 \[2.59--6.21\]                                     6.23   0.000^[\*](#tf5){ref-type="table-fn"}^   29.93                             0.002   63   Random   0.142
   β-lactam and/or β-lactamase inhibitor   4    320/775     3.56 \[0.85--14.87\]                                    1.74   0.08                                     51.82                             0.000   94   Random   0.509
   Cephalosporins                          8    533/1,037   1.64 \[0.90--2.98\]                                     1.63   0.10                                     27.69                             0.000   75   Random   0.734
   Aminolycosides                          8    533/1,037   2.05 \[1.43--2.94\]                                     3.91   0.000^[\*](#tf5){ref-type="table-fn"}^   8.75                              0.27    20   Fixed    0.366
   Glycopeptides                           3    226/694     2.40 \[1.09--5.27\]                                     2.18   0.03^[\*](#tf5){ref-type="table-fn"}^    6.41                              0.04    69   Random   0.326
   Quinolones                              10   601/1,302   2.28 \[1.40--3.70\]                                     3.32   0.000^[\*](#tf5){ref-type="table-fn"}^   26.66                             0.002   66   Random   0.101
   Metronidazole                           3    184/244     0.68 \[0.14--3.29\]                                     0.48   0.63                                     11.43                             0.003   82   Random   0.890
   Anti-pseudomonal penicillins            5    263/319     2.67 \[1.78--4.01\]                                     4.73   0.000^[\*](#tf5){ref-type="table-fn"}^   2.01                              0.73    0    Fixed    0.495

Mean difference.

*p* \< 0.05.

CI, confidence interval; DM, diabetes mellitus; LOS, length of hospital stay; MD, mean difference; OR, odds ratio.

PARP of risk factors {#s011}
--------------------

The PARP of risk factors for CRKP infection was further carried out. The calculation of PARP can help us to learn the main risk factors of CRKP infection. [Table 3](#T3){ref-type="table"} shows that the PARP of previous antibiotic use was up to 62.42%. In addition, other variables, such as admission to ICU (PARP = 25.03%); prior hospitalization (PARP = 27.48%); use of CVC (PARP = 40.37%), MV (PARP = 34.56%), presence of tracheostomy (PARP = 25.08%), and parenteral nutrition (PARP = 19.12%); carbapenems (PARP = 34.46%), quinolones (PARP = 23.87%), and anti-pseudomonal penicillins (PARP = 24.80%) exposure were also high-risk factors for CRKP infection. The risk factors LOS, days of ICU stay are not displayed in [Table 3](#T3){ref-type="table"} because the original literatures did not provide sufficient information on the calculation of the *P~e~* value.

###### 

[The Population Attributable Risk Proportion of Risk Factors for Carbapenem-Resistant *K. pneumoniae* Infection]{.smallcaps}

  Risk factor                    OR \[95% CI\]         P~e~*(%)*   PARP (%)
  ------------------------------ --------------------- ----------- ----------
  Previous antibiotic use        3.31 \[1.68--6.49\]   71.89       62.42
  CVC use                        2.30 \[1.26--4.19\]   52.07       40.37
  MV                             2.54 \[1.67--3.85\]   34.29       34.56
  Carbapenems                    4.01 \[2.59--6.21\]   17.47       34.46
  Prior hospitalization          1.85 \[1.12--3.07\]   44.59       27.48
  Tracheostomy                   3.63 \[1.47--9.00\]   12.73       25.08
  Admission to ICU               2.48 \[1.90--3.23\]   22.56       25.03
  Anti-pseudomonal penicillins   2.67 \[1.78--4.01\]   19.75       24.80
  Quinolones                     2.28 \[1.40--3.70\]   24.50       23.87
  Parenteral nutrition           2.38 \[1.68--3.36\]   17.13       19.12
  Glycopeptides                  2.40 \[1.09--5.27\]   15.71       18.03
  Steroid use                    1.43 \[1.04--1.96\]   22.35       8.77
  Transplant recipient           2.01 \[1.03--3.92\]   8.49        7.90
  Aminoglycosides                2.05 \[1.43--2.94\]   8.10        7.84

*P~e~*, pool exposure rate; PARP, population attributable risk proportion.

Sensitivity analyses {#s012}
--------------------

Comparison of the results of pooled ORs for the random-effects and fixed-effects models through sequential and one-by-one omission of individual studies revealed that the corresponding results were not significantly different in most of the risk factors and that the heterogeneity indicators were reduced in some conditions. However, when we removed the studies of Correa *et al*.,^[@B33]^ or Gómez Rueda and Zuleta Tobón,^[@B13]^ or Patel *et al.*,^[@B21]^ the ORs and the corresponding 95% CIs for transplant recipient changed to 1.86 (95% CI = \[0.85--4.07\]), 1.98 (95% CI = \[0.81--4.85\]), and 1.49 (95% CI = \[0.86--2.61\]), respectively. Similarly, when we removed the study of Correa,^[@B33]^ the ORs and the corresponding 95% CI for steroids use changed from 1.43 (95% CI = \[1.04--1.96\]) to 1.34 (95% CI = \[0.97--1.86\]). The results changed and became statistically insignificant for the transplant recipient factor and steroids use factor.

Publication bias {#s013}
----------------

The publication bias among the included studies was evaluated with the Egger\'s test, which had stronger statistical power to provide evidence of publication bias.^[@B36]^ No obvious asymmetry of the risk factors was observed except tracheostomy (*p* = 0.036), and the results are shown in [Table 2](#T2){ref-type="table"}.

Discussion {#s014}
==========

In this meta-analysis, we aimed to identify the risk factors of CRKP infection by summarizing the results of relevant articles published so far. Since it was first identified in North Carolina in 1996, CRKP has become the most frequent CRE species found in the United States.^[@B35]^ CRKP has also been endemic in other areas worldwide, including China,^[@B37]^ Israel,^[@B38]^ a number of South America countries,^[@B39],[@B40]^ and Europe, especially Greece and Italy.^[@B7]^ The rapid and global dissemination of CRKP has become a substantial concern in healthcare facilities. Infections with such strains are difficult to eradicate and have a limited treatment options. Therefore, determining the possibility of CRKP infection in early stage through risk factors and taking reasonable prevention could be helpful to reduce the incidence rate of CRKP infection. Although some studies on the risk factors of CRKP infection are previously available, their results are not always consistent. These differences could be due to the insufficient statistical power of individual studies with small sample sizes or the variations that exist in different selection criteria and study designs. Furthermore, no meta-analysis study exists on this topic until now. Accordingly, we performed this meta-analysis to identify the relationship between risk factors and CRKP infection.

In consideration of the defined inclusion and exclusion criteria, 3,627 participants were included in our study. Most of the eligible studies clearly manifested the total sample size, inclusion and exclusion criteria of subjects, and characteristics of participants. Furthermore, all the included studies were evaluated as high quality during the quality assessment. Thus, we concluded that the results based on existing evidence were relatively convincing. The 16 included articles mainly originated from eight nations, 4 were published in the United States,^[@B21],[@B23],[@B27],[@B31]^ where the CRKP was the most prevalent strain among CRE; 5 were from Greece and Italy,^[@B16],[@B25],[@B26],[@B30],[@B32]^ the two countries with the highest percentage of CRKP in Europe,^[@B41]^ which also contributed to the vast majority of infection proportion; and the remaining were from China, Brazil, Colombia, Turkey, and Israel, where CRKP infection was geographically epidemic. Among these studies, one^[@B27]^ only focused on urinary tract infection, three^[@B25],[@B26],[@B32]^ focused on bloodstream infection, and the rest included patients with different infection types.

In this meta-analysis, we found that previous antibiotic use is a risk factor for CRKP infection, and the PARP of the previous antibiotic use up to 62.42% was the highest PARP of our analysis, indicating that diverse specific antibiotics have been utilized across published studies and previous antibiotic use is an important risk factor of CRKP infection. In our meta-analysis, patients exposed to main antibiotics, such as carbapenems, aminoglycosides, glycopeptides, quinolones, and anti-pseudomonal penicillins, have a higher risk of acquiring CRKP infection. These factors were determined as such because antibiotic selective pressure is the main cause of the drug-resistant strain infections. A study has suggested that the use of carbapenem antibiotics was closely related to the production of *K. pneumoniae* carbapenemase.^[@B42]^ Increased exposure to one antibiotic group boosts the effect of exposure to the other antibiotic group on CRKP infection risk.^[@B43]^ Therefore, combined use of antibiotics and longer treatment with carbapenems in large doses have increased the antibiotic selection pressure, allowing carbapenem-resistant bacteria to develop a plethora of carbapenem resistance mechanisms.^[@B44]^

Undergoing invasive procedures increases the risk of infection. However, our meta-analysis revealed that only the use of CVC, MV, tracheostomy, and parenteral nutrition exhibited statistical significance. Intubation or tracheotomy destroys the normal human body barrier, which facilitates contact between the interior of the human body and the external environment, causing opportunistic pathogens to easily invade and attach to the inner wall of the intubation where they form a biofilm cover that is difficult to eradicate; consequently, the pathogenic bacteria can enter the deep tissue of the body, increasing the chance of CRKP infection.^[@B45]^ Notably, we found a publication bias for tracheostomy among the studies using Egger\'s (*p* = 0.036) test, which may be caused by the inclusion of few component studies and the small sample size. Therefore, further studies about the relationship between tracheostomy and CRKP infection are needed.

Furthermore, our study found that prior hospitalization and longer LOS were risk factors for CRKP infection development. The result may be explained by the fact that patients with previous hospitalization and longer LOS before CRKP infection have an increased infection risk because of prolonged exposure to invasive devices or antibiotic use.^[@B13]^ Similarly, admission to ICU is closely associated with the occurrence of CRKP infection. Compared with the non-infected patients, those with CRKP infection have prolonged days of ICU stay. Carbapenem resistance is more common among *Klebsiella* spp. isolated from the ICU compared with non-ICU isolates patients.^[@B46]^ This finding may be because ICU patients are usually extremely vulnerable and critically ill with a prolonged hospital stay, various antibiotic types and dosages exposure, and a high number of invasive procedures performed. Furthermore, carbapenems are the mainstay empiric antibiotic therapy for severe ICU-acquired infections caused by drug-resistant Gram-negative bacteria, which may further explain the emergence of CRKP infection in the ICU.^[@B47]^

In our study, we provided statistically significant evidence for transplant recipient and steroids use, but the findings were sometimes unstable. The results changed and became statistically insignificant for the transplant recipient factor when the studies of Correa *et al.*,^[@B33]^ or Gómez Rueda and Zuleta Tobón,^[@B13]^ or Patel *et al.*^[@B21]^ were removed. In addition, the result of steroids use factor also became statistically insignificant with the removal of the study of Correa *et al.*.^[@B33]^ The results of the two sensitivity analyses could be attributed to the small sample size, which led to the overrating of the combined effect and the inversion of the conclusion.

We should also pay attention to several limitations of our study, which may affect the results. First, we only included published studies from five databases. Hence, relevant articles published in other databases and unpublished studies might have been missed. Second, we excluded some studies because of an unclear diagnosis criterion of infection or they did not distinguish the outcomes of infected patients from those of colonized patients, which led to the extremely small dataset collection in the inclusion and limited the statistical power to detect possible independent risk factors for CRKP infection. Third, significant heterogeneity was detected in some risk factors because we had strict enrollment criteria of references (only included case--control or cohort study). In addition, the inclusive studies were conducted in different countries, and some diagnostic levels and the basic condition of the eligible patients might have varied significantly. Therefore, the heterogeneity between the included studies could be high.

In conclusion, we identified a number of factors associated with CRKP infection development. These findings may provide impetus for infection control, promote rational use of available antibiotics, and provide containment of CRKP spread. Further well-designed and large randomized controlled trials and other intervention evaluation studies are needed to develop effective preventive and therapeutic protocols for CRKP infection in the future.
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